[{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"MK-0616","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck Group \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"MK-0616","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"MK-0616","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for MK-0616

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : MK-0616 is an investigational macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors resulting in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.

                          Brand Name : MK-0616

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          August 25, 2023

                          Lead Product(s) : MK-0616

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : MK-0616 is an investigational macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors resulting in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.

                          Brand Name : MK-0616

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          March 06, 2023

                          Lead Product(s) : MK-0616

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : MK-0616 is an investigational macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors resulting in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.

                          Brand Name : MK-0616

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          February 21, 2023

                          Lead Product(s) : MK-0616

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank